MicroPort Scientific Corp (HKG: 0853), a leading medical device company based in China, has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), has entered into a distribution framework agreement with Dongguan Kewei Medical Instrument Co., Ltd. Kewei, which was acquired by MicroPort Scientific in 2012, has agreed to grant CardioFlow exclusive rights to distribute its products in China. In return, CardioFlow has agreed to provide a loan of RMB 10 million (USD 1.38 million) to Kewei.
The products covered by the distribution agreement are the Evermend series of occluders, which include the Evermenid ASD (Atrial Septal Defect) occluder, Evermenid VSD (Ventricular Septal Defect) occluder, Evermenid PDA (Patent Ductus Arteriosus) occluder, and the Evermenid occluder delivery system. These products are known for their superior biocompatibility, precise positioning, and ease of release. They are currently registered for use in China, Brazil, Ecuador, Mexico, Kazakhstan, and other countries, highlighting their global reach and acceptance.- Flcube.com
